Evidence map›Paper›PMID 41799529›Full record

ArticleOncology research2026

Min Dong, Zongchang Song, Xiaohui Lu, Minxue Lu, Chen Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Min DongDepartment of Oncology, No. 960 Hospital of PLA, Jinan, China.
Zongchang SongDepartment of Oncology, Shanghai University Affiliated Mengchao Cancer Hospital, Shanghai, China.
Xiaohui LuDepartment of Oncology, No. 960 Hospital of PLA, Jinan, China.
Minxue LuDepartment of Gastroenterology, Huzhou College Affiliated Nantaihu Hospital, Huzhou, China.
Chen ZhongDepartment of Oncology, No. 960 Hospital of PLA, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer (GC) remains highly lethal, with metabolic reprogramming as a key hallmark. This study explores Centromere Protein F (CENPF)'s role in GC pathogenesis, specifically its regulation of glutamine metabolism. Methods: The Cancer Genome Atlas-Stomach Adenocarcinoma (TCGA-STAD), GSE19826, and GSE27342 datasets were analyzed by bioinformatics to identify key candidate genes in GC. The function of Results: Conclusion: Our findings identify a new

Indexed as

Chromosomal Proteins, Non-HistoneGlutaminaseGlutamineMicrofilament ProteinsProto-Oncogene Proteins c-mycStomach NeoplasmsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingUp-Regulationcentromere protein FChromosomal Proteins, Non-HistoneGLS protein, humanGlutaminaseGlutamineMicrofilament ProteinsMYC protein, humanProto-Oncogene Proteins c-myccellular myelocytomatosisCentromere protein Fgastric cancerglutaminaseglutamine metabolism reprogramming

Identifiers

PMID41799529
PMCPMC12963658

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.